Showing 7521-7530 of 8465 results for "".
- Dermira's Investigational AD Drug Performs Well in Phase 2b Trial, Shares Skyrockethttps://practicaldermatology.com/news/ready-for-phase-3-dermiras-investigational-ad-drug-performs-well-in-phase-2b-trial/2459969/All three doses of Dermira, Inc.’s lebrikizumab showed greater improvements in the Eczema Area and Severity Index in a new Phase 2b dose-ranging study of adults with moderate-to-severe atopic dermatitis, and shares of D
- FDA Approves Dupixent for Moderate to Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-approves-dupixent-for-moderate-to-severe-atopic-dermatitis-in-adolescents/2459975/The FDA has approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged 12 through 17 whose disease is not adequately controlled with topical prescription
- 2019 NewBeauty Awards: Alastin's TransFORM Body Treatment Acknowledged for Innovationhttps://practicaldermatology.com/news/2019-newbeauty-awards-alastins-transform-body-treatment-acknowledged-for-innovation/2459977/ALASTIN Skincare, Inc’s TransFORM Body Treatment has been awarded a 2019 NewBeauty Award in the innovations category. NewBeauty acknowledges the best products, treatments and trends in cosmetics and aesthetics with their innovation category described as, "the future is now
- Patricia Altavilla Named New CEO at Suneva Medicalhttps://practicaldermatology.com/news/patricia-altavilla-named-new-ceo-at-suneva-medical/2459982/Patricia Altavilla is the new Chief Executive Officer of Suneva® Medical, Inc. An industry vet, Altavilla began her career at Mentor Corporation, serving as Vice President of International Sales and Worldwide Marketing. For n
- Cheryl Deguara Returns to Sciton in New Rolehttps://practicaldermatology.com/news/cheryl-deguara-returns-to-sciton-in-new-role/2459985/Cheryl Deguara, PhD is the new Senior Director, Product Innovation & Clinical Research at Sciton. A Sciton alum, Deguara earned her PhD from Vanderbilt University in Biochemistry and has an extensive background i
- Almirall: Positive Data for KX2-391 for AKs; ThermiGen to be Divestedhttps://practicaldermatology.com/news/almirall-positive-data-for-kx2-391-for-aks-thermigen-to-be-divested/2459986/Results from two Phase III studies of KX2-391, also known as KX-01 ointment, in the treatment of actinic keratosis show positive results. The findings have been presented at the 2019 American Academy of Dermatology Annual Meeting in Washington, DC and were
- Candela Unveils New Corporate Identity at the 2019 AAD Annual Meetinghttps://practicaldermatology.com/news/candela-unveils-new-corporate-identity-at-the-2019-aad-annual-meeting/2459874/Syneron-Candela has rebranded the company to Candela and unveiled its new corporate branding at the American Academy of Dermatology (AAD) Annual Meeting. The new corporate identity reflects the unification of the Syneron and Candela brands and is designed to support continued global market growth
- Floodwaters and Climate Change Increase Risks for Dermatologic Diseasehttps://practicaldermatology.com/news/floodwaters-and-climate-change-increase-risks-for-dermatologic-disease/2459879/As more frequent and intense flooding disasters have occurred in conjunction with progressively rising temperatures, both disaster victims and relief workers have experienced significant dermatologic problems, according to
- Meet AAD's New Officers and Board of Directorshttps://practicaldermatology.com/news/meet-aads-new-officers-and-board-of-directors/2459880/The American Academy of Dermatology (AAD) is set to install four new officers and four new members of its board of directors at the conclusion of the 2019 AAD Annual Meeting in Washington. The new members will also hold the same positions for the American Academy of Dermatology Associat
- FDA Approves Janssen's Tremfya One-Presshttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-one-press/2459882/The FDA has approved Tremfya® One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. Tremfya®(guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson